Compare Amgen, Inc. (AMGN) vs Blackrock Inc (BLK) Price & Performance

Amgen, Inc.Trade

Blackrock IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Blackrock Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Blackrock Inc trades at $1,144.15 (market cap $177.92B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.

	AMGN	BLK
Market Cap	$224.14B	$177.92B
Sector	Health	Financials
52-Week High	$417.20	$1.20K
52-Week Low	$271.18	$922.90
Enterprise Value	$267.45B	$179.02B
Dividend Yield	2.43%	2%
Volume	—	641,547

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

BLK

Nio shares drop 5% after BlackRock reduces stake despite strong delivery growth.24/7 Wall Street · 1 day agoBearish Nvidia leads $500B Wall Street consortium to finance AI infrastructure expansion.24/7 Wall Street · 1 day agoBullish Wall Street giants plan $500B to finance AI infrastructure as a new asset class, says Nvidia CEO.CNBC · 1 day agoBullish View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.